This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bergman, I. Articles by Slamon, D. J. Search for Related Content PubMed PubMed Citation Articles by Bergman, I. Articles by Slamon, D. J.

Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody¹

Departments of Pediatrics [I. B., J. A. G.], Neurology [I. B.], and Pathology [M. A. B.] University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213; and Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, California 90024 [D. J. S.]

The metastatic spread of breast cancer to the leptomeninges (LM) is a painful, debilitating, and usually lethal condition. Current therapies are generally ineffective or extremely toxic. The current study evaluated monoclonal antibody therapy in an animal model of LM human breast cancer. Monoclonal antibody 4D5, which recognizes the extracellular domain of the HER2/neu receptor, was administered into the cerebrospinal fluid of athymic rats implanted with human breast cancer cell lines. Continuous intraventricular administration of 4D5 inhibited growth of SKBR3 cells that overexpress HER2/neu but not of MCF7 cells, which do not. Inhibition was dose-dependent, with higher doses of 4D5 producing an improved response. i.p. administration of cisplatin in addition to 4D5 did not improve results. Continuous administration of 4D5 into the lumbar, as opposed to the ventricular intrathecal space, was not therapeutically effective. Treatment with 4D5 did not result in outgrowth of cells lacking expression of the HER2/neu receptor. These results suggest that 4D5, administered regionally, may palliate LM metastases from HER2/neu-overexpressing breast carcinoma.

This article has been cited by other articles:

				Y. Gao, P. Whitaker-Dowling, S. C. Watkins, J. A. Griffin, and I. Bergman Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J. Virol., September 1, 2006; 80(17): 8603 - 8612. [Abstract] [Full Text] [PDF]

				R. J. Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg Breast Cancer Metastasis to the Central Nervous System Am. J. Pathol., October 1, 2005; 167(4): 913 - 920. [Abstract] [Full Text] [PDF]

				H. Ochiai, S. A. Moore, G. E. Archer, T. Okamura, T. A. Chewning, J. R. Marks, J. H. Sampson, and M. Gromeier Treatment of Intracerebral Neoplasia and Neoplastic Meningitis with Regional Delivery of Oncolytic Recombinant Poliovirus Clin. Cancer Res., July 15, 2004; 10(14): 4831 - 4838. [Abstract] [Full Text] [PDF]